Sera Prognostics Announces Board Transition as Growth Continues

Sera Prognostics Undergoes Board Transition

Sera Prognostics Inc., known as The Pregnancy Company, focused on enhancing maternal and neonatal health, has made an important announcement regarding its board of directors. The company, listed on Nasdaq under the ticker symbol SERA, revealed that Jeff Elliott will be leaving his position on the board effective June 4, 2026. This decision comes as Mr. Elliott has expressed his intention not to seek re-election at the upcoming Annual Meeting of Shareholders.

Since joining the board in March 2025, Elliott has provided valuable direction and insight during a critical phase of growth and development for Sera. He shared, "I have greatly valued my time serving on Sera's Board and remain confident in the Company's mission and long-term opportunity. However, due to increasing demands on my time, I believe stepping down is in the best interest of the organization to ensure it receives focused leadership."

Zhenya Lindgardt, the CEO of Sera, offered gratitude on behalf of the board and management team, acknowledging Elliott's thoughtful guidance which greatly influenced the company’s strategic path. Lindgardt noted, "Jeff's perspective has helped shape our strategy, and we are grateful for the role he has played in our progress."

As the company moves forward, it aims to maintain strong corporate governance and is currently engaged in discussions with several highly qualified candidates for potential board appointments, with an announcement expected soon.

About Sera Prognostics

Sera Prognostics is a pioneering health diagnostics firm committed to bettering the health outcomes of women and infants through precision pregnancy care. The company’s mission centers around delivering crucial pregnancy-related information to improve the wellbeing of mothers and newborns, ultimately contributing to reduced healthcare costs. They boast an innovative product line focused on the early diagnosis of preterm birth risks and other pregnancy complications.

One of Sera’s prominent offerings is the PreTRM® Test, a diagnostic tool licensed to evaluate the individual risk of premature delivery during pregnancy. By identifying women at risk between weeks 18 and 20 of their pregnancy journey, healthcare providers can implement timely interventions. This unique blood test measures protein biomarkers that predict potential complications linked to preterm births.

Preterm Birth and Its Implications

Preterm birth is categorized as any birth that occurs before the 37th week of gestation, and it serves as a major contributor to neonatal health challenges. According to the March of Dimes Report Card from 2025, the United States received a D+ grade for preterm births for the fourth consecutive year—indicating a troubling trend in public health. Prematurity can lead to serious long-term health complications, including disabilities, cerebral palsy, and other health issues that markedly increase lifetime healthcare costs. Estimates suggest that managing the health implications of preterm births in the U.S. resulted in approximately $25 billion in 2016.

The PreTRM® Test is the only commercially available blood test validated for its predictive capability regarding spontaneous preterm births in asymptomatic single pregnancies. Its introduction into clinical practice allows medical professionals to make informed decisions tailored to each patient’s unique risk profile, thereby ensuring personalized and effective care.

As Sera Prognostics continues to push the envelope in maternal and child health diagnostics, the leadership transition signifies both challenges and opportunities ahead. The company is dedicated to furthering its mission and expanding its positive impact on healthcare for mothers and babies across the globe.

Conclusion

Sera Prognostics is at a pivotal juncture with the upcoming board transition. As the company prepares to embrace new leadership, it remains focused on refining and enhancing its innovative product offerings and facilitating better health outcomes for women and their children. The presence of seasoned professionals on the board will aim to drive forward Sera's objectives in the domain of pregnancy care, showcased through their commitment to groundbreaking solutions like the PreTRM® Test.